Genetic Technologies Limited (NASDAQ:GENE) shares shot up 2.2% during trading on Monday . The company traded as high as $2.85 and last traded at $2.29, 75,697 shares traded hands during mid-day trading. A decline of 30% from the average session volume of 108,662 shares. The stock had previously closed at $2.24.
Separately, ValuEngine downgraded Genetic Technologies from a “buy” rating to a “hold” rating in a report on Monday, May 13th.
The business has a fifty day moving average price of $1.01 and a 200 day moving average price of $0.85.
Genetic Technologies Company Profile (NASDAQ:GENE)
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Featured Article: Why is cost of goods sold important?
Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.